Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Organogenesis Holdings Inc.NASDAQ: ORGO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$56.1M, compared with -$19.5M a year earlier. Trailing-twelve-month EBITDA was $37.31M. Over 3 fiscal years it compounded at +22.4% a year.
Context
- EBITDA amounted to 13.1% of revenue in FY2025, up 9.9 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$161.63M (-318.7%) for the fiscal year ending Dec 2026, a slowdown from the +368.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$56.1M-179.6% QoQ
- Last fiscal yearDec 2025
- $73.91M+368.9% YoY
- LTMMar 2026
- $37.31M+1061.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -187.7% | -644.5% | -456.8 pp |
| 1 year | +368.9% | -318.7% | -687.6 pp |
| 3-year CAGR | +22.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 73.91M USD
- Year-over-year change
- +368.9%
- 4-year CAGR
- -4.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.91M | +368.9% |
| FY2024 | 2024-12-31 | 15.76M | -56.3% |
| FY2023 | 2023-12-31 | 36.03M | -10.6% |
| FY2022 | 2022-12-31 | 40.32M | -53.7% |
| FY2021 | 2021-12-31 | 87M | — |
EBITDA vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1061.2% is the highest of 11, against a peer median of +2.4%.
- EBITDA amounts to 7.3% of revenue for ORGO, versus a peer median of 7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $154.5M USD | +28.1% | +148.3% | 22.8% | |
| LTM Mar 2026 | CA$49.42M CAD | +201.3% | — | 5.3% | |
| LTM Mar 2026 | $39.9M USD | +145.1% | — | 9.5% | |
| LTM Mar 2026 | $37.31M USD | +1061.2% | +22.4% | 7.3% | |
| LTM Mar 2026 | $27.5M USD | -56.2% | -11.5% | 29.3% | |
| LTM Feb 2026 | -$5.44M USD | -1089.6% | -46.2% | 1.7% | |
| LTM Apr 2026 | -$6.2M USD | -108.2% | -68.7% | 0.7% | |
| LTM Mar 2026 | -$14.03M USD | +53.2% | — | 4.6% | |
| LTM Mar 2026 | -$15.64M USD | +5.6% | — | — | |
| LTM Mar 2026 | -$67.05M USD | -25.2% | — | — | |
| LTM Mar 2026 | -$211.5M USD | -0.8% | — | 333.1% | |
| Peer median (excluding ORGO) | — | +2.4% | -28.8% | 7.4% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 467.36M | 450.89M | 433.14M | 482.04M | 563.03M |
| Cost of Revenue | 114.2M | 105.02M | 106.48M | 115.74M | 137.52M |
| Gross Profit | 353.16M | 345.87M | 326.66M | 366.3M | 425.51M |
| Gross Margin | 75.6% | 76.7% | 75.4% | 76.0% | 75.6% |
| Research & Development | 30.74M | 39.76M | 44.38M | 50.27M | 44.54M |
| Selling, General & Admin | 250.2M | 283.81M | 269.75M | 294.51M | 326.24M |
| Operating Expenses | 280.94M | 323.57M | 314.13M | 367.59M | 369.64M |
| Depreciation & Amortization | 16.68M | 18.03M | 23.45M | 17.03M | 26.94M |
| EBITDA | 87M | 40.32M | 36.03M | 15.76M | 73.91M |
| EBITDA Margin | 18.6% | 8.9% | 8.3% | 3.3% | 13.1% |
| Operating Income | 72.22M | 22.3M | 12.53M | (1.28M) | 55.87M |
| Operating Margin | 15.5% | 4.9% | 2.9% | -0.3% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 2.28M |
| Interest Expense | 7.24M | 2.01M | 2.19M | 1.54M | 0 |
| Other Income / Expenses | (9.13M) | (2.02M) | (2.13M) | (1.52M) | (8.9M) |
| Income Before Tax | 63.09M | 20.28M | 10.39M | (2.81M) | 46.97M |
| Pre-Tax Margin | 13.5% | 4.5% | 2.4% | -0.6% | 8.3% |
| Income Tax Expense | (31.12M) | 4.75M | 5.45M | (3.67M) | 9.94M |
| Net Income | 94.2M | 15.53M | 4.95M | 861K | 37.03M |
| Net Margin | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| EPS (Basic) | 0.73 | 0.12 | 0.04 | (0.01) | 0.16 |
| EPS (Diluted) | 0.70 | 0.12 | 0.04 | (0.01) | 0.15 |
| Weighted Avg Shares | 128.33M | 130.07M | 131.23M | 131.67M | 126.74M |
| Weighted Avg Shares (Diluted) | 133.66M | 132.38M | 132.75M | 131.67M | 130.25M |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.